Daily Glucose Profiles after Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus.

Takahara M, Shiraiwa T, Katakami N, Maeno Y, Yamamoto K, Shiraiwa Y, Yoshida Y, Kozawa J, Shimomura I

Internal medicine (Tokyo, Japan)24 May 2023Cited by 2 (Europe PMC)

PMID37225492PMCIDPMC10824647DOI10.2169/internalmedicine.1441-22PepBankPUB-37225492

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, mean glucose rose by 9 mg/dL after switching from injectable to oral semaglutide (from 132 to 141 mg/dL).
In plain wordsIn adults with type 2 diabetes, average glucose was slightly higher after switching from injected to oral semaglutide.
Peptide
Semaglutide
Outcome
IncreaseMean glucose change after switch to oral semaglutide
Study
n = 23
Comparator
Injectable semaglutide 0.5 mg once weekly (before switch)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg increased to 7 mg once daily · oral · 2 monthsAs given in this study (human).
Measurements
Mean glucose change
9 mg/dL
after switch
Mean glucose
132 mg/dL
before switch
Mean glucose
141 mg/dL
after switch
Source sentences
Summary
Results Mean glucose levels significantly increased by 9 mg/dL on average, from 132±20 to 141±27 mg/dL (p=0.047), which was equivalent to a change of 0.2% in the estimated hemoglobin A1c (6.5±0.5% to 6.7±0.7%).
3 context sentences(design, population, supporting numbers)
Summary · context
Objective This prospective observational study explored the changes in the daily glycemic profile after switching from injectable to oral semaglutide in patients with type 2 diabetes mellitus.
Summary · context
Methods Patients with type 2 diabetes mellitus who were treated with once-weekly 0.5 mg injectable semaglutide and wished to switch to once-daily oral semaglutide participated in this study.
Summary · context
Patients Twenty-three patients participated.
Report a problemFND-3722549201
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, estimated HbA1c rose by 0.2% after switching from injectable to oral semaglutide (from 6.5% to 6.7%).
In plain wordsIn adults with type 2 diabetes, estimated HbA1c was slightly higher after switching from injected to oral semaglutide.
Peptide
Semaglutide
Outcome
IncreaseEstimated HbA1c after switch
Study
n = 23
Comparator
Injectable semaglutide 0.5 mg once weekly (before switch)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg increased to 7 mg once daily · oral · 2 monthsAs given in this study (human).
Measurements
Estimated HbA1c change
0.2%
after switch
Estimated HbA1c
6.5%
before switch
Estimated HbA1c
6.7%
after switch
Source sentences
Summary
which was equivalent to a change of 0.2% in the estimated hemoglobin A1c (6.5±0.5% to 6.7±0.7%).
3 context sentences(design, population, supporting numbers)
Summary · context
Objective This prospective observational study explored the changes in the daily glycemic profile after switching from injectable to oral semaglutide in patients with type 2 diabetes mellitus.
Summary · context
Methods Patients with type 2 diabetes mellitus who were treated with once-weekly 0.5 mg injectable semaglutide and wished to switch to once-daily oral semaglutide participated in this study.
Summary · context
Patients Twenty-three patients participated.
Report a problemFND-3722549202
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes, the inter-individual variability of glucose, measured as standard deviation, rose after switching to oral semaglutide.
In plain wordsAfter switching from injected to oral semaglutide, glucose levels varied more between people.
Peptide
Semaglutide
Outcome
IncreaseInter-individual glucose variability
Study
n = 23
Comparator
Injectable semaglutide 0.5 mg once weekly (before switch)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
3 mg increased to 7 mg once daily · oral · 2 monthsAs given in this study (human).
Source sentences
Summary
The inter-individual variability assessed with standard deviation also significantly increased (p=0.004).
3 context sentences(design, population, supporting numbers)
Summary · context
Objective This prospective observational study explored the changes in the daily glycemic profile after switching from injectable to oral semaglutide in patients with type 2 diabetes mellitus.
Summary · context
Methods Patients with type 2 diabetes mellitus who were treated with once-weekly 0.5 mg injectable semaglutide and wished to switch to once-daily oral semaglutide participated in this study.
Summary · context
Patients Twenty-three patients participated.
Report a problemFND-3722549203
04HumanObservational studyOther
In adults with type 2 diabetes, the change in treatment satisfaction after the switch varied considerably, with no specific trend overall.
In plain wordsAfter switching to oral semaglutide, treatment satisfaction changed differently from patient to patient, with no clear overall trend.
Peptide
Semaglutide
Outcome
No significant changeTreatment satisfaction
Study
n = 23
Comparator
Injectable semaglutide 0.5 mg once weekly (before switch)
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
3 mg increased to 7 mg once daily · oral · 2 monthsAs given in this study (human).
Source sentences
Summary
The change in treatment satisfaction varied considerably among patients, with no specific trend in the overall population.
3 context sentences(design, population, supporting numbers)
Summary · context
Objective This prospective observational study explored the changes in the daily glycemic profile after switching from injectable to oral semaglutide in patients with type 2 diabetes mellitus.
Summary · context
Methods Patients with type 2 diabetes mellitus who were treated with once-weekly 0.5 mg injectable semaglutide and wished to switch to once-daily oral semaglutide participated in this study.
Summary · context
Patients Twenty-three patients participated.
Report a problemFND-3722549204
05HumanObservational studyOther
After trying oral semaglutide, 48% of patients preferred the oral formulation, 35% preferred the injectable and 17% had no preference.
In plain wordsAfter trying oral semaglutide, 48% of patients preferred the tablet, 35% preferred the injection and 17% had no preference.
Peptide
Semaglutide
Outcome
Not applicableFormulation preference
Study
n = 23
Comparator
Injectable semaglutide 0.5 mg once weekly (before switch)
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
3 mg increased to 7 mg once daily · oral · 2 monthsAs given in this study (human).
Measurements
Prefer oral
48%
patients
Prefer injectable
35%
patients
No preference
17%
patients
Source sentences
Summary
After trying oral semaglutide, 48% of patients responded that they preferred the oral formulation, while 35% preferred the injectable formulation, and 17% had no preference.
3 context sentences(design, population, supporting numbers)
Summary · context
Objective This prospective observational study explored the changes in the daily glycemic profile after switching from injectable to oral semaglutide in patients with type 2 diabetes mellitus.
Summary · context
Methods Patients with type 2 diabetes mellitus who were treated with once-weekly 0.5 mg injectable semaglutide and wished to switch to once-daily oral semaglutide participated in this study.
Summary · context
Patients Twenty-three patients participated.
Report a problemFND-3722549205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.